welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Cardiac Magnetic Resonance in Children With Muscular Dystrophy
study id #: NCT01081080
condition: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Limb Girdle Muscular Dystrophy
This protocol will exploit novel state of the art cardiovascular magnetic resonance techniques to examine important changes in the heart in children with muscular dystrophy. The purpose of this study is to compare cardiac magnetic resonance (CMR) with the collected cardiac outcome data obtained in protocol: PITT1109 – Cardiac Outcome Measures in Children with Muscular Dystrophy.
mechanism of action: No pharmaceutical intervention
last updated: November 22, 2018
start date: April 2010
estimated completion: October 2011
size / enrollment: 20
Participant enrolled in the CINRG study: PITT1109 - Cardiac Outcome Measures in Children with Muscular Dystrophy
• Pregnant woman (when uncertain, participants will undergo urine testing) or lactating women
• Decompensated congestive heart failure (unable to lie flat during CMR)
• Impaired renal excretory function (calculated Glomerular Filtration Rate less than 30mL/min)
• Contra-indications to Magnetic Resonance Imaging:
-Cardiac pacemaker or implantable defibrillator
-Cerebral aneurysm clip
-Metallic ocular foreign body
-Any implanted device (i.e. insulin pump, drug infusion device)
-Metal shrapnel or bullet
Study of Eteplirsen in Young Patients With DMD Amenable to Exon 51 SkippingThis is a multicenter, open-label, dose-...
How Facebook and Twitter could be the next disruptive force in clinical trialsAmber Sapp was browsing the Internet lat...
Catabasis Pharmaceuticals Announces Publication Of Phase 1 Clinical Results Of Edasalonexent (CAT-1004) In Duchenne ...Catabasis Pharmaceuticals, Inc., a clini...
Lower Limb Flexibility in Duchenne Muscular Dystrophy: Effects on Functional PerformanceThe investigator investigated the effect...
Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-infl...We report a first-in-patient study of va...
Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDACapricor Therapeutics, a clinical-stag...
Catabasis Quarterly: Updates on edasalonexent and clinical trialsHappy New Year! As 2019 kicks off, our P...